- Report
- November 2024
- 500 Pages
Global
From €3659EUR$3,995USD£3,115GBP
- Report
- December 2024
- 150 Pages
Global
From €5449EUR$5,950USD£4,639GBP
- Report
- August 2024
- 120 Pages
Global
From €5449EUR$5,950USD£4,639GBP
- Report
- May 2025
- 250 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Conference
- November 2025
- 1 Day
Global
€789EUR$892USD£649GBP
€911EUR$1,029USD£749GBP
- Conference
- July 2025
- 1 Day
Global
€789EUR$892USD£649GBP
€911EUR$1,029USD£749GBP
- Report
- May 2024
- 343 Pages
Global
From €4395EUR$4,799USD£3,742GBP
- Report
- September 2023
- 150 Pages
Africa
From €5449EUR$5,950USD£4,639GBP
- Report
- June 2019
- 248 Pages
Global
From €1763EUR$1,925USD£1,501GBP
€2519EUR$2,750USD£2,144GBP
- Report
- February 2024
- 110 Pages
Global
From €4121EUR$4,500USD£3,509GBP
- Report
- November 2023
- 30 Pages
Global
From €2976EUR$3,250USD£2,534GBP

Advanced Therapy Medicinal Products (ATMPs) are a class of pharmaceuticals that are used to treat serious or life-threatening diseases and conditions. They are based on gene therapy, somatic cell therapy, and tissue engineering, and are designed to modify or replace a patient's cells or tissues. ATMPs are highly complex and require specialized manufacturing processes, and are subject to stringent regulatory requirements.
ATMPs are used to treat a wide range of diseases, including cancer, genetic disorders, and degenerative diseases. They are also used to treat conditions such as organ failure, autoimmune diseases, and cardiovascular diseases. ATMPs are often used in combination with other treatments, such as chemotherapy or radiation therapy.
Some companies in the ATMP market include Novartis, Gilead Sciences, Celgene, and Regeneron Pharmaceuticals. Show Less Read more